Skip to main content
Top
Published in: Supportive Care in Cancer 10/2012

01-10-2012 | Original Article

Chemotherapy line-associated differences in quality of life in patients with advanced cancer

Authors: B. Mayrbäurl, L. M. Wintner, J. M. Giesinger, Th. Himmelfreundpointner, S. Burgstaller, B. Holzner, J. Thaler

Published in: Supportive Care in Cancer | Issue 10/2012

Login to get access

Abstract

Purpose

The aim of this study was to investigate quality of life (QOL) differences between patients receiving first, second, or third-line palliative chemotherapy (CT).Furthermore, QOL was also compared to a sex- and age-matched sample of healthy controls.

Methods

Patients with different metastatic cancers receiving palliative CT were approached to complete the EORTC QLQ-C30 questionnaire by means of touch-screen computers before the start of CT, after 3 cycles and at the end of cytostatic treatment.

Results

One hundred four patients were recruited for QOL assessment (56.9% of patients in first, 22.5% second and 20.6% third- or above-line palliative CT). Compared to healthy controls, they suffered from substantial QOL impairments in all EORTC QLQ-C30 sub-domains. In regard to CT lines, patients with first-line CT reached better scores in emotional and social functioning than second-line patients and less financial difficulties than third-line patients. Despite the high level of impairment in the patient sample, electronic data collection proved to be feasible and well accepted.

Conclusions

The results indicate that patients receiving third- or above-line palliative CT are confronted with stronger QOL impairments than first- and second-line patients. Supported by its feasibility and acceptance of by patients, electronic QOL data capture is an attractive method to screen for symptoms and track their course within clinical routine.
Literature
1.
go back to reference Iconomou G, Mega V, Koutras A, Iconomou Alexander V, Kalofonos Haralabos P (2004) Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. Cancer 101(2):404–411PubMedCrossRef Iconomou G, Mega V, Koutras A, Iconomou Alexander V, Kalofonos Haralabos P (2004) Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. Cancer 101(2):404–411PubMedCrossRef
2.
go back to reference Taenzer P, Bultz BD, Carlson LE, Speca M, DeGagne T, Olson K, Doll R, Rosberger Z (2000) Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients. Psychooncology 9(3):203–213PubMedCrossRef Taenzer P, Bultz BD, Carlson LE, Speca M, DeGagne T, Olson K, Doll R, Rosberger Z (2000) Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients. Psychooncology 9(3):203–213PubMedCrossRef
3.
go back to reference Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK (2002) Role of health-related quality of life in palliative chemotherapy treatment decisions. J Clin Oncol 20(4):1056–1062PubMedCrossRef Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK (2002) Role of health-related quality of life in palliative chemotherapy treatment decisions. J Clin Oncol 20(4):1056–1062PubMedCrossRef
4.
go back to reference Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 22(4):714–724PubMedCrossRef Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, Selby PJ (2004) Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol 22(4):714–724PubMedCrossRef
5.
go back to reference Allenby A, Matthews J, Beresford J, McLachlan SA (2002) The application of computer touch-screen technology in screening for psychosocial distress in an ambulatory oncology setting. Eur J Cancer Care (Engl) 11(4):245–253CrossRef Allenby A, Matthews J, Beresford J, McLachlan SA (2002) The application of computer touch-screen technology in screening for psychosocial distress in an ambulatory oncology setting. Eur J Cancer Care (Engl) 11(4):245–253CrossRef
6.
go back to reference Drummond HE, Ghosh S, Ferguson A, Brackenridge D, Tiplady B (1995) Electronic quality of life questionnaires: a comparison of pen-based electronic questionnaires with conventional paper in a gastrointestinal study. Qual Life Res 4(1):21–26PubMedCrossRef Drummond HE, Ghosh S, Ferguson A, Brackenridge D, Tiplady B (1995) Electronic quality of life questionnaires: a comparison of pen-based electronic questionnaires with conventional paper in a gastrointestinal study. Qual Life Res 4(1):21–26PubMedCrossRef
7.
go back to reference Velikova G, Wright EP, Smith AB, Cull A, Gould A, Forman D, Perren T, Stead M, Brown J, Selby PJ (1999) Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires. J Clin Oncol 17(3):998–1007PubMed Velikova G, Wright EP, Smith AB, Cull A, Gould A, Forman D, Perren T, Stead M, Brown J, Selby PJ (1999) Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires. J Clin Oncol 17(3):998–1007PubMed
8.
go back to reference Taenzer PA, Speca M, Atkinson MJ, Bultz BD, Page S, Harasym P, Davis JL (1997) Computerized quality-of-life screening in an oncology clinic. Cancer Pract 5(3):168–175PubMed Taenzer PA, Speca M, Atkinson MJ, Bultz BD, Page S, Harasym P, Davis JL (1997) Computerized quality-of-life screening in an oncology clinic. Cancer Pract 5(3):168–175PubMed
9.
go back to reference Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19(5):1266–1274PubMed Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19(5):1266–1274PubMed
10.
go back to reference Albers P, Siener R, Hartlein M, Fallahi M, Haeutle D, Perabo FG, Steiner G, Blatter J, Muller SC (2002) Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma—prognostic factors for response and improvement of quality of life. Onkologie 25(1):47–52PubMedCrossRef Albers P, Siener R, Hartlein M, Fallahi M, Haeutle D, Perabo FG, Steiner G, Blatter J, Muller SC (2002) Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma—prognostic factors for response and improvement of quality of life. Onkologie 25(1):47–52PubMedCrossRef
11.
go back to reference Bang S-M, Park Se H, Kang Hee G, Jue Jung I, Cho In H, Yun Young H, Cho Eun K, Shin Dong B, Lee Jae H (2005) Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer 13(7):515–521PubMedCrossRef Bang S-M, Park Se H, Kang Hee G, Jue Jung I, Cho In H, Yun Young H, Cho Eun K, Shin Dong B, Lee Jae H (2005) Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer 13(7):515–521PubMedCrossRef
12.
go back to reference Joly F, Houede N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, Rolland F, Flechon A, Henry-Amar M, Culine S (2009) Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer 7(2):E28–E33PubMedCrossRef Joly F, Houede N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, Rolland F, Flechon A, Henry-Amar M, Culine S (2009) Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer 7(2):E28–E33PubMedCrossRef
13.
go back to reference Guntinas-Lichius O, Ruhlow S, Veelken F, Klussmann JP (2009) Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J Cancer Res Clin Oncol 135(7):901–908PubMedCrossRef Guntinas-Lichius O, Ruhlow S, Veelken F, Klussmann JP (2009) Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J Cancer Res Clin Oncol 135(7):901–908PubMedCrossRef
14.
go back to reference Ngeow J, Lim WT, Leong SS, Ang MK, Toh CK, Gao F, Chowbay B, Tan EH (2011) Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol 22(3):718–722PubMedCrossRef Ngeow J, Lim WT, Leong SS, Ang MK, Toh CK, Gao F, Chowbay B, Tan EH (2011) Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Ann Oncol 22(3):718–722PubMedCrossRef
15.
go back to reference Giesinger J, Kemmler G, Mueller V, Zabernigg A, Mayrbaeurl B, Thaler J, Ofner D, Pegger C, Rumpold G, Weber B, Sperner-Unterweger B, Holzner B (2009) Are gender-associated differences in quality of life in colorectal cancer patients disease-specific? Qual Life Res 18(5):547–555PubMedCrossRef Giesinger J, Kemmler G, Mueller V, Zabernigg A, Mayrbaeurl B, Thaler J, Ofner D, Pegger C, Rumpold G, Weber B, Sperner-Unterweger B, Holzner B (2009) Are gender-associated differences in quality of life in colorectal cancer patients disease-specific? Qual Life Res 18(5):547–555PubMedCrossRef
16.
go back to reference Holzner B, Zabernigg A, Kemmler G, Baier S, Kopp M, Sperner Unterweger B (2004) Computerized assessment of quality of life in patients undergoing chemotherapy. Qual Life Res 13(9):1523 Holzner B, Zabernigg A, Kemmler G, Baier S, Kopp M, Sperner Unterweger B (2004) Computerized assessment of quality of life in patients undergoing chemotherapy. Qual Life Res 13(9):1523
17.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef
18.
go back to reference Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144PubMed Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144PubMed
19.
go back to reference Giesinger J, Kemmler G, Meraner V, Gamper EM, Oberguggenberger A, Sperner-Unterweger B, Holzner B (2009) Towards the implementation of quality of life monitoring in daily clinical routine: methodological issues and clinical implication. Breast Care (Basel) 4(3):148–154CrossRef Giesinger J, Kemmler G, Meraner V, Gamper EM, Oberguggenberger A, Sperner-Unterweger B, Holzner B (2009) Towards the implementation of quality of life monitoring in daily clinical routine: methodological issues and clinical implication. Breast Care (Basel) 4(3):148–154CrossRef
20.
go back to reference Barclay-Goddard R, Epstein JD, Mayo NE (2009) Response shift: a brief overview and proposed research priorities. Qual Life Res 18(3):335–346PubMedCrossRef Barclay-Goddard R, Epstein JD, Mayo NE (2009) Response shift: a brief overview and proposed research priorities. Qual Life Res 18(3):335–346PubMedCrossRef
21.
go back to reference Sprangers MA (2010) Disregarding clinical trial-based patient-reported outcomes is unwarranted: Five advances to substantiate the scientific stringency of quality-of-life measurement. Acta Oncol 49(2):155–163PubMedCrossRef Sprangers MA (2010) Disregarding clinical trial-based patient-reported outcomes is unwarranted: Five advances to substantiate the scientific stringency of quality-of-life measurement. Acta Oncol 49(2):155–163PubMedCrossRef
22.
go back to reference Giesinger JM, Wintner LM, Oberguggenberger AS, Gamper EM, Fiegl M, Denz H, Kemmler G, Zabernigg A, Holzner B (2011) Quality of life trajectory in patients with advanced cancer during the last year of life. J Palliat Med 14(8):904–912PubMedCrossRef Giesinger JM, Wintner LM, Oberguggenberger AS, Gamper EM, Fiegl M, Denz H, Kemmler G, Zabernigg A, Holzner B (2011) Quality of life trajectory in patients with advanced cancer during the last year of life. J Palliat Med 14(8):904–912PubMedCrossRef
23.
go back to reference Sahlberg-Blom E, Ternestedt BM, Johansson JE (2001) Is good ‘quality of life’ possible at the end of life? An explorative study of the experiences of a group of cancer patients in two different care cultures. J Clin Nurs 10(4):550–562PubMedCrossRef Sahlberg-Blom E, Ternestedt BM, Johansson JE (2001) Is good ‘quality of life’ possible at the end of life? An explorative study of the experiences of a group of cancer patients in two different care cultures. J Clin Nurs 10(4):550–562PubMedCrossRef
24.
go back to reference Mullen KH, Berry DL, Zierler BK (2004) Computerized symptom and quality-of-life assessment for patients with cancer part II: acceptability and usability. Oncol Nurs Forum 31(5):E84–E89PubMedCrossRef Mullen KH, Berry DL, Zierler BK (2004) Computerized symptom and quality-of-life assessment for patients with cancer part II: acceptability and usability. Oncol Nurs Forum 31(5):E84–E89PubMedCrossRef
25.
go back to reference Bush N, Donaldson G, Moinpour C, Haberman M, Milliken D, Markle V, Lauson J (2005) Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation. Qual Life Res 14(7):77–93PubMedCrossRef Bush N, Donaldson G, Moinpour C, Haberman M, Milliken D, Markle V, Lauson J (2005) Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation. Qual Life Res 14(7):77–93PubMedCrossRef
26.
go back to reference Hawkins R, Grunberg S (2009) Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. Clin J Oncol Nurs 13(1):54–64PubMedCrossRef Hawkins R, Grunberg S (2009) Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. Clin J Oncol Nurs 13(1):54–64PubMedCrossRef
27.
go back to reference Balducci L, Stanta G (2000) Cancer in the frail patient. A coming epidemic. Hematol Oncol Clin North Am 14(1):235–250, xiPubMedCrossRef Balducci L, Stanta G (2000) Cancer in the frail patient. A coming epidemic. Hematol Oncol Clin North Am 14(1):235–250, xiPubMedCrossRef
28.
go back to reference Zagonel V, Fratino L, Piselli P, Milan I, La Conca G, Serraino D, Monfardini S (2002) The comprehensive geriatric assessment (CGA) predicts mortality among elderly cancer patients (ECP). Proc Am Soc Clin Oncol 21: 2002 (abstr 1458). Zagonel V, Fratino L, Piselli P, Milan I, La Conca G, Serraino D, Monfardini S (2002) The comprehensive geriatric assessment (CGA) predicts mortality among elderly cancer patients (ECP). Proc Am Soc Clin Oncol 21: 2002 (abstr 1458).
Metadata
Title
Chemotherapy line-associated differences in quality of life in patients with advanced cancer
Authors
B. Mayrbäurl
L. M. Wintner
J. M. Giesinger
Th. Himmelfreundpointner
S. Burgstaller
B. Holzner
J. Thaler
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1355-x

Other articles of this Issue 10/2012

Supportive Care in Cancer 10/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine